Do HIV shots every 8 weeks work better than daily pills for teens?
Yes. In a randomized trial of 476 teenagers with HIV in Africa, HIV injections every 8 weeks kept the virus under control better than daily pills. By week 96, the virus came back in 0.9% of teens getting shots, compared with 6.4% of teens who stayed on pills.
Teenagers with HIV tend to have worse treatment results than other age groups. The drugs are not weaker for them. The hard part is swallowing a pill every single day, for years, through school, friendships, and everything else adolescence brings. Missed doses add up, and the virus can come back.
Long-acting injections take the daily pill out of the picture. This trial, called LATA and published in The Lancet, tested whether HIV shots every 8 weeks could replace daily tablets for teens whose virus was already fully controlled. The trial was set up to show the shots were no worse. They did better than that.
What the data show
Researchers enrolled 476 adolescents aged 12 to 19 from five clinics in Kenya, South Africa, Uganda, and Zimbabwe. Every one of them already had an undetectable viral load for more than a year. Half kept taking a daily three-drug pill (dolutegravir, lamivudine, and tenofovir, often called TLD). The other half switched to two drugs, cabotegravir and rilpivirine, given as a shot into the muscle every 8 weeks after a short starting phase.
The main question was simple: did the virus come back? The researchers counted a “rebound” when two viral load tests in a row showed 50 copies per mL or higher. By week 96, that happened in 2 of 235 teens on shots and 15 of 241 on pills.
In absolute terms, the shots cut the rebound rate by about 5.5 percentage points. Put another way, for about every 18 teens switched from pills to shots, one fewer had the virus return over two years. The range of likely results runs from about 1.5 to 10.3 percentage points fewer rebounds. In relative terms, that is roughly 86% fewer rebounds. The chance this gap was a fluke is about 1 in 770 (p = 0.0013). The shots passed the “no worse than pills” test and then cleared the higher bar of being better.
Dr. Kumar’s Take
This is a practical win, not a pharmacology win. The pills in this trial are excellent drugs. The problem is that a teenager has to take them every day for the rest of their life, and adolescence is the hardest stretch to do that. A shot every 8 weeks instead of a pill every day changes the math.
The setting matters too. This trial ran in five African clinics, not in a wealthy-country research center. Almost all of these teens (98%) got HIV from their mothers, and they had been on treatment for a median of about 12 years already. These are kids who have spent most of their lives on daily pills.
The comparison was also a tough one. The pill group took a modern three-drug combination, and the shots still came out ahead. The researchers concluded that the shots support a real maintenance option for this age group, with no new safety concerns.
Safety, limits, and caveats
The safety picture looked similar between the two groups. Serious adverse events occurred in 14 teens on shots and 12 on pills, with no clear difference (hazard ratio 1.16, and the true effect could plausibly be anywhere from about half to about two and a half times the risk). The only serious side effect tied to the shots was one hypersensitivity (allergic-type) reaction. Among more severe side effects overall, there were four injection-site reactions in the shot group. Seven teens stopped the shots permanently over the course of follow-up, for reasons that included side effects, a new tuberculosis infection, planning a pregnancy, and personal choice.
There are real limits. The trial was open-label, so teens and doctors knew who got which treatment. Only the lab staff measuring viral loads were kept in the dark. The results also apply to teens who already had the virus fully suppressed with no history of treatment failure. They do not tell us how the shots work for someone starting treatment or whose virus is not under control.
Practical takeaways
- If you are a parent or caregiver of a teen with well-controlled HIV who struggles with daily pills, ask the care team whether long-acting injections every 8 weeks are an option.
- The shots in this trial were studied only in teens whose virus was already undetectable for more than a year, so getting to that point on pills first is part of the path.
- Shots every 8 weeks only work if the visits happen on time, so a reliable clinic schedule matters as much as the drug itself.
- Tell the care team about any rash, allergic symptoms, or soreness at the injection site, since those were the side effects linked to the shots.
Related Studies and Research
- Can a weekly HIV pill replace the daily one?
- New mRNA flu vaccine works better than standard flu shots in older adults
- Can a daily pill keep weight off after weight-loss shots?
- Daily TMS therapy: the depression treatment that works in just 6 weeks
FAQs
What is cabotegravir-rilpivirine?
It is a two-drug HIV treatment given as injections into the muscle instead of pills. In this trial, each visit delivered 600 mg of cabotegravir and 900 mg of rilpivirine. Teens got shots at weeks 4, 8, and 16, then every 8 weeks after that. That works out to one clinic visit roughly every two months in place of a daily tablet.
Can a teenager with HIV switch from pills to shots?
In this trial, the teens who switched were 12 to 19 years old, had an undetectable viral load for more than 12 months, and had never had their treatment fail. That is the group the results apply to. Someone whose virus is not yet controlled, or who has had treatment fail before, was not part of this study. Whether switching makes sense for a specific teen is a decision for their HIV care team.
Do HIV injections have more side effects than pills?
Not in this trial. Serious side effects and more severe side effects happened at similar rates in both groups. The shot group had a few injection-site reactions, which is expected with any injection, and one serious allergic-type reaction linked to the drug. Seven teens stopped the shots for good over the whole study, and only two of those were because of side effects from the shots.
Bottom Line
In 476 teenagers with HIV in Kenya, South Africa, Uganda, and Zimbabwe, switching from daily pills to cabotegravir-rilpivirine shots every 8 weeks kept the virus suppressed better over 96 weeks. The virus came back in 0.9% of teens on shots versus 6.4% on pills, about one fewer rebound for every 18 teens switched, with no new safety concerns. For young people who find a daily pill hard to keep up with, a shot every two months is a strong option.
